## **Supplementary Material Table of Contents**

Supplemental Figure 1. In situ hybridization of Spry1.

Supplemental Figure 2. Lineage analysis of Fgf20<sup>Cre</sup>.

Supplemental Figure 3. *Fgf9* and *Fgf20* are not required for cell death and proliferation of E10.5 nephron progenitors.

Supplemental Figure 4. Fgf9 and Fgf20 regulate genes required for renal branching.

Supplemental Figure 5. Fgf20 does not affect renal phenotypes caused by loss of Fgf8.

Supplemental Figure 6. Fgf8 and Fgf20 regulate genes required for renal branching.

## **Supporting Figure Legends**

**Supplemental Figure 1.** *In situ* hybridization of *Spry1*. (A-C) sectional *in situ* hybridization of *Spry1* in E11.5 (A), E13.5 (B), and E14.5 (C) kidneys showing that *Spry1* is expressed in both UB and NPC. UB, ureteric bud. NPC, nephron progenitor cells.

**Supplemental Figure 2. Lineage analysis of** *Fgf20*<sup>Cre</sup>. (A) Sectional view of a whole P0 kidney labeled with tdTomato showing high efficiency of Cre recombinase. (B-D) colabeling Six2 (B), FoxD1 (C), and DBA (D) with tdTomato in P0 *Fgf20*<sup>Cre/+</sup>;*ROSA*<sup>tdTomato/+</sup> kidneys showing that tdTomato labels nephron progenitors but not stromal progenitor or ureteric buds. Scale bar, 100μm.


Supplemental Figure 3. *Fgf9* and *Fgf20* are not required for cell death and proliferation of E10.5 nephron progenitors. (A-D) Six2 staining of E10.5 *Fgf9* and *Fgf20* compound mutant kidneys. (E-H) Six2 and EdU staining of E10.5 *Fgf9* and *Fgf20* compound mutant kidneys. (I-L) Pax2 and TUNEL staining of E10.5 *Fgf9* and *Fgf20* compound mutant kidneys. (M-O) Quantifying the number of nephron progenitors (M), proliferation index (N), and cell death index (O) of *Fgf9* and *Fgf20* compound mutant kidneys showing no changes in all genotypes. Data is shown with mean±S.D. Scale bar, 100µm.

Supplemental Figure 4. *Fgf9* and *Fgf20* regulate genes required for renal branching. (A-H) *Ret in situ* hybridization of E10.5 (A-D) and E11.5 (E-H) *Fgf9* and *Fgf20* compound mutant embryos showing renal branching is delayed in E11.5 *Fgf9*-/+;*Fgf20*-/- and regressed in *Fgf9*-/-;*Fgf20*-/-. (I-L) *Gdnf in situ* hybridization of E11.5 *Fgf9* and *Fgf20* compound mutant embryos showing that *Gdnf* expression was decreased in *Fgf9*-/-;*Fgf20*-/-. (M-P) *Etv4 in situ* hybridization of E11.5 *Fgf9* and *Fgf20* compound mutant embryos showing that *Etv4* expression was decreased in *Fgf9*-/-;*Fgf20*-/-. (Q-S) *Etv5 in situ* hybridization of E11.5 *Fgf9* and *Fgf20* compound mutant embryos showing that *Etv5* expression was decreased in *Fgf9*-/-;*Fgf20*-/-. And diminished in *Fgf9*-/-;*Fgf20*-/-. Scale bar, 500µm.

Supplemental Figure 5. Fgf20 does not affect renal phenotypes caused by loss of Fgf8. (A-C) Wnt9b in situ hybridization of E14.5 Fgf8 and Fgf20 compound mutant kidneys showing no changes in all genotypes. (D-F) Wnt4 in situ hybridization of E14.5

Fgf8 and Fgf20 compound mutant embryos showing that Wnt4 expression was diminished in Fgf8<sup>fl/+</sup>;Fgf20<sup>Cre/+</sup> but not in Fgf8<sup>fl/+</sup>;Fgf20<sup>Cre/-</sup>. Scale bar, 500μm.

Supplemental Figure 6. *Fgf8* and *Fgf20* regulate genes required for renal branching. (A-D) *Pax2 in situ* hybridization of E11.5 *Fgf8* and *Fgf20* compound mutant embryos showing that *Pax2* expression was decreased in both *Fgf8*<sup>fl/+</sup>;*Fgf20*<sup>Cre/+</sup> and *Fgf8*<sup>fl/+</sup>;*Fgf20*<sup>Cre/-</sup>. (E-L) *Ret in situ* hybridization of E11 (E-H) and E11.5 (I-L) *Fgf8* and *Fgf20* compound mutant embryos showing delayed ureteric bud bifurcation in *Fgf8*<sup>fl/-</sup>;*Fgf20*<sup>Cre/-</sup>, *Fgf8*<sup>fl/+</sup>;*Fgf20*<sup>Cre/-</sup>, and *Fgf8*<sup>fl/-</sup>;*Fgf20*<sup>Cre/-</sup>. (M-P) *Gdnf in situ* hybridization of E11.5 *Fgf8* and *Fgf20* compound mutant embryos showing that *Gdnf* expression is decreased in *Fgf8*<sup>fl/-</sup>;*Fgf20*<sup>Cre/-</sup> and diminished in *Fgf8*<sup>fl/-</sup>;*Fgf20*<sup>Cre/-</sup>. (Q-T) *Etv4 in situ* hybridization of E11.5 *Fgf8* and *Fgf20* compound mutant embryos showing that *Etv4* expression is decreased in *Fgf8*<sup>fl/-</sup>;*Fgf20*<sup>Cre/-</sup> and diminished in *Fgf8*<sup>fl/-</sup>;*Fgf20*<sup>Cre/-</sup>. (U-X) *Etv5 in situ* hybridization of E11.5 *Fgf8* and *Fgf20* compound mutant embryos showing that *Etv* expression is decreased in *Fgf8*<sup>fl/-</sup>;*Fgf20*<sup>Cre/-</sup> and *Fgf8*<sup>fl/-</sup>;*Fgf20*<sup>Cre/-</sup> and diminished in *Fgf8*<sup>fl/-</sup>;*Fgf20*<sup>Cre/-</sup>. Yellow arrows point to metanephric zone. Scale bar, 500µm.



Fgf20<sup>Cre/+</sup>;ROSA<sup>tdTomato/+</sup>

